Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.
2.

Developing drugs for cognitive impairment in schizophrenia.

Breier A.

Schizophr Bull. 2005 Oct;31(4):816-22. Epub 2005 Sep 8. Review.

3.

Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment.

Sharma T, Antonova L.

Psychiatr Clin North Am. 2003 Mar;26(1):25-40. Review.

PMID:
12683258
4.

Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.

Green MF, Nuechterlein KH, Gold JM, Barch DM, Cohen J, Essock S, Fenton WS, Frese F, Goldberg TE, Heaton RK, Keefe RS, Kern RS, Kraemer H, Stover E, Weinberger DR, Zalcman S, Marder SR.

Biol Psychiatry. 2004 Sep 1;56(5):301-7. Review.

PMID:
15336511
5.

Recent advances in treating cognitive impairment in schizophrenia.

Galletly C.

Psychopharmacology (Berl). 2009 Jan;202(1-3):259-73. doi: 10.1007/s00213-008-1302-9. Epub 2008 Sep 3. Review.

PMID:
18766331
6.

Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review.

Saavedra-Velez C, Yusim A, Anbarasan D, Lindenmayer JP.

J Clin Psychiatry. 2009 Jan;70(1):104-12. Epub 2008 Nov 18. Review.

PMID:
19026265
7.

Better pharmacotherapy for schizophrenia: what does the future hold?

Webber MA, Marder SR.

Curr Psychiatry Rep. 2008 Aug;10(4):352-8. Review.

PMID:
18627675
8.

Pharmacological strategies for enhancing cognition in schizophrenia.

Barch DM.

Curr Top Behav Neurosci. 2010;4:43-96. Review.

PMID:
21312397
9.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
10.

Oral cholinesterase inhibitor add-on therapy for cognitive enhancement in schizophrenia: a quantitative systematic review, Part I.

Chouinard S, Sepehry AA, Stip E.

Clin Neuropharmacol. 2007 May-Jun;30(3):169-82. Review.

PMID:
17545751
11.

The neurobiology of cognition in schizophrenia.

Tamminga CA.

J Clin Psychiatry. 2006;67 Suppl 9:9-13; discussion 36-42. Review.

12.

[Treatment of cognitive deficits in schizophrenia. Part 1: Diagnostic and psychological training].

Pfueller U, Roesch-Ely D, Mundt C, Weisbrod M.

Nervenarzt. 2010 May;81(5):556-63. doi: 10.1007/s00115-009-2923-x. Review. German.

PMID:
20195566
13.

Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.

Houthoofd SA, Morrens M, Sabbe BG.

Clin Ther. 2008 Sep;30(9):1565-89. doi: 10.1016/j.clinthera.2008.09.014. Review.

PMID:
18840365
14.
15.

Treatment of cognitive deficits in schizophrenia.

Bowie CR, Harvey PD.

Curr Opin Investig Drugs. 2006 Jul;7(7):608-13. Review.

PMID:
16869112
16.
17.

Treating cognitive dysfunction in patients with schizophrenia.

Galletly CA, Clark CR, MacFarlane AC.

J Psychiatry Neurosci. 2000 Mar;25(2):117-24. Review.

18.

Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.

Tcheremissine OV, Castro MA, Gardner DR.

Expert Opin Investig Drugs. 2012 Jan;21(1):7-14. doi: 10.1517/13543784.2012.634798. Epub 2011 Nov 8. Review.

PMID:
22059602
19.

A review of cognitive training in schizophrenia.

Twamley EW, Jeste DV, Bellack AS.

Schizophr Bull. 2003;29(2):359-82. Review.

20.

[Measuring the cognitive deficit associated with schizophrenia: presentation of the MATRICS neuropsychological test battery].

Sarolta K, Pál C, István B.

Neuropsychopharmacol Hung. 2007 Oct;9(3):143-50. Review. Hungarian. Erratum in: Neuropsychopharmacol Hung. 2007 Dec;9(4):207.

Items per page

Supplemental Content

Write to the Help Desk